Valiant Laboratories

Valiant Laboratories Acquisitions (Net)

The Acquisitions (Net) of Valiant Laboratories (VALIANTLAB.NS) as of Nov 4, 2026 is 610.86 M INR. In the previous year, Acquisitions (Net) was -980.07 M INR — a change of -162.33% (higher).

Acquisitions (Net)

610.86 MINR

YoY

-162.33%

Last updated:

Acquisitions (Net) of Valiant Laboratories is 2025 610.86 M INR. Acquisitions (Net) of Valiant Laboratories was 2024 -980.07 M INR. It decreases by -162.33% higher compared to the previous year.

The Valiant Laboratories Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2023
-174.87 M INR
Jan 1, 2024
-980.07 M INR
Jan 1, 2025
610.86 M INR
The Valiant Laboratories Acquisitions (Net) history
YEARAcquisitions (Net)YoY
610.86 MINR-162.33%
-980.07 MINR+460.45%
-174.87 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valiant Laboratories Stock analysis

What does Valiant Laboratories do? Valiant Laboratories Ltd manufactures paracetamol API/bulk drug for pharmaceutical applications, targeting medical conditions such as headache, muscle ache, arthritis, back ache, toothache, cold, and fever. The company operates a single manufacturing facility at Tarapur industrial estate, approximately 150 km from Nhava Sheva Port (JNPT), producing specialty chemicals and pharma intermediates for domestic and international markets. Its subsidiary, VALIANT ADVANCED SCIENCES PRIVATE LIMITED, supports the company's operations in the pharmaceutical sector. The firm's primary revenue comes from selling paracetamol API and specialty chemicals to pharmaceutical companies and distributors globally. Manufacturing focuses on high-demand applications like pain relief and fever treatment, with products distributed across India and abroad. The company leverages its Tarapur facility's proximity to Nhava Sheva Port for efficient export logistics. Valiant Laboratories Ltd serves the pharmaceutical industry by supplying essential active ingredients, particularly paracetamol, which is widely used in over-the-counter medications. The company's manufacturing capabilities for specialty chemicals and pharma intermediates cater to both domestic and international clients seeking reliable API sources. Its single-location production model ensures focused resource allocation for consistent output quality. Valiant Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valiant Laboratories stock

Acquisitions (Net) of Valiant Laboratories is 610.86 M INR in 2025.

Acquisitions (Net) of Valiant Laboratories changed from -980.07 M INR to 610.86 M INR, representing a -162.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) Valiant Laboratories since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s Valiant Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Valiant Laboratories

All Key Metrics — Valiant Laboratories